
Immatics NV (IMTX) Stock Forecast & Price Target
Immatics NV (IMTX) Analyst Ratings
Bulls say
Immatics NV's ACTengine platform showcases enhanced logistics compared to existing solid tumor cell therapies, potentially streamlining production and administration processes. The company is positioned to achieve significant monotherapy activity, with a target of at least a 20% overall response rate (ORR) and a minimum progression-free survival (mPFS) duration of four months, which could strengthen investor confidence in its therapeutic offerings. Additionally, positive responses are anticipated to increase with higher dose levels, further supporting Immatics's potential for strong clinical outcomes and revenue growth in the oncology market.
Bears say
Immatics NV's stock outlook is negatively affected by the underwhelming clinical data from Brenetafusp presented at ASCO '24, which reported only an 11% overall response rate (ORR) and a 56% disease control rate (DCR) among second-line melanoma patients. The company's risk profile includes significant R&D, regulatory, and commercial challenges, potential competition, and the prospects of lower-than-expected sales combined with dilutive financing, which may exceed prior assumptions. Furthermore, a downside scenario predicts a valuation drop to approximately $3 per share if key pipeline programs, including SUPRAME and others, fail to meet critical milestones or deliver disappointing updates.
This aggregate rating is based on analysts' research of Immatics NV and is not a guaranteed prediction by Public.com or investment advice.
Immatics NV (IMTX) Analyst Forecast & Price Prediction
Start investing in Immatics NV (IMTX)
Order type
Buy in
Order amount
Est. shares
0 shares